StemBios Technologies, Inc., USA
Title: The application for the SB small stem cell
Wang brings extensive experiences in stem cell research. He was the Senior Scientist/Director of MorphoGen Pharmaceuticals which is a pioneer stem cell company focusing on muscle-derived stem cells. Prior to MorphoGen, Dr. Wang was at VitaGen which is a cell-therapy company dedicated to treating fulminant hepatic failure using bioartificial liver devices. Dr. Wang received his Ph.D. in Molecular Biology at Vanderbilt University. He completed his postdoctoral work at The Salk and Burnham Institute in La Jolla, California. Before joining StemBios, Dr. Wang was an assistant research professor at City of Hope Medical Center. Current, Dr. Wang is a Chief Scientific Officer in StemBios to lead the stem cell research. He is the co-inventor of several patents and numerous scientific publications.
Small stem cells, such as spore-like cells, blastomere-like stem cells (BLSCs), and very-small embryonic-like stem cells (VSELs) have been described and debated in recent studies, although their multipotency in human tissues has not yet been confirmed. Here, we report the discovery of adult multipotent stem cells derived from human bone marrow, which we call StemBios (SB) cells. These isolated SB cells are smaller than 6 micron and are DAPI+ and Lgr5+ (Leucine-Rich Repeat Containing G Protein-Coupled Receptor 5). Here, we discuss the SB cells and its application.